Borderline Resectable Pancreatic Cancer Neoadjuvant Chemoradiotherapy Clinicaltrial-1

Inclusion Criteria:

* Age≥18 years old and ≤80 years old;
* Histological proven pancreatic adenocarcinoma;
* Borderline resectable pancreatic cancer proven by imaging examinations via multidisciplinary approaches according to NCCN guidelines;
* No prior chemotherapy or radiotherapy;
* ECOG of 0 or 1;
* Routine blood test: absolute neutrophil count\>1500/mm3, platelet\>100000/mm3;
* Normal liver function: serum total bilirubin≤2.0mg/dl, ALT and AST\<2.5 times of the upper limit of normal value;
* Normal kidney function: serum creatinine\<1.5 times of the upper limit of normal value or creatinine clearance rate\>45ml/min;
* No severe comorbidities.

Exclusion Criteria:

* Metastatic pancreatic cancer;
* Patients who had surgeries, chemotherapy or other treatments before inclusion;
* Impaired organ functions: heart failure (New York Heart Association III-IV), coronary heart disease, myocardial infarction within 6 months, severe cardiac arrhythmia and respiratory failure;
* Confirmed other cancer within 5 years;
* Pregnant women or lactating women;
* Patients enrolled in other clinical trials or incompliant of regular follow up;
* Patients who did not provide an informed consent.